Hereditary Cancer Testing

BRCA1 & BRCA2 By NGS (Germline)

Advanced NGS-based germline testing for hereditary breast and ovarian cancer risk assessment.

BRCA1 & BRCA2 NGS Technology Blood (EDTA) SNVs & InDels Coding + Splice Sites 14 Working Days

About the Test

Identify Inherited BRCA Gene Mutations with High Accuracy

BRCA1 and BRCA2 are tumour suppressor genes responsible for repairing damaged DNA. Harmful inherited mutations in these genes significantly increase the lifetime risk of developing breast, ovarian, pancreatic, prostate and male breast cancers.

This NGS-based germline test performs comprehensive sequencing of the coding regions and splice-site junctions of both genes, enabling accurate detection of clinically relevant genetic variants.

Genes Analysed

BRCA1 & BRCA2

Sample Type

Peripheral Blood (EDTA)

Technology

Next Generation Sequencing

Turnaround Time

~14 Working Days

Advanced NGS Technology for Accurate BRCA Analysis

Behind BRCA Testing

The BRCA1 & BRCA2 Germline Test utilizes Next Generation Sequencing (NGS) technology to comprehensively analyze hereditary cancer-associated genes. It provides reliable detection of clinically significant variants with high analytical accuracy.

Genes Analysed

Comprehensive analysis of BRCA1 and BRCA2 genes associated with hereditary cancer predisposition.

Regions Covered

Full coding regions along with clinically relevant splice-site junctions for comprehensive variant detection.

Variant Detection

Detects Single Nucleotide Variants (SNVs) and small Insertions & Deletions (InDels) with high precision.

High Confidence Results

Expert bioinformatics analysis and clinical interpretation ensure reliable and actionable genetic insights.

Recommended For

Who Should Consider BRCA Testing?

BRCA1 & BRCA2 germline testing is recommended for individuals with personal or family histories suggestive of hereditary breast and ovarian cancer syndrome.

Family History

Individuals with multiple relatives diagnosed with breast, ovarian or related cancers.

Early-Onset Breast Cancer

Patients diagnosed with breast cancer at a young age.

Known BRCA Mutation

Family members of individuals carrying a pathogenic BRCA mutation.

Clinical Risk Assessment

Individuals referred by clinicians for hereditary cancer risk evaluation.

Clinical Significance

Cancers Associated with BRCA1 & BRCA2 Mutations

Pathogenic variants in BRCA1 and BRCA2 significantly increase the lifetime risk of several hereditary cancers. Identifying these mutations enables informed clinical management and personalized surveillance strategies.

Breast Cancer

Increased hereditary risk in both women and men.

Ovarian Cancer

One of the strongest hereditary associations with BRCA mutations.

Prostate Cancer

Important for hereditary prostate cancer risk assessment.

Pancreatic Cancer

BRCA mutations are associated with increased pancreatic cancer susceptibility.

Male Breast Cancer

BRCA2 mutations significantly increase hereditary risk.

Testing Workflow

How BRCA Testing Works

From sample collection to report generation, every step follows standardized laboratory protocols to ensure accurate and reliable hereditary cancer risk assessment.

Blood Sample Collection

Peripheral blood (EDTA) sample is collected for genetic analysis.

DNA Extraction

High-quality genomic DNA is isolated from the blood sample.

NGS Sequencing

BRCA genes are sequenced using advanced Next Generation Sequencing.

Expert Analysis

Bioinformatics pipeline identifies clinically significant variants.

Report Delivery

Comprehensive report delivered within 14 working days.

Safe & Secure

Your data is protected at every step.

Highly Accurate

Advanced NGS ensures precise results.

Expert Reviewed

Interpreted by clinical genetics experts.

Timely Results

Reports delivered within 14 working days.

Clinical Indications

Who Should Consider This Test?

BRCA1 & BRCA2 testing is recommended for individuals with a personal or family history suggestive of hereditary breast and ovarian cancer syndrome.

Family History of Cancer

Individuals with first- or second-degree relatives diagnosed with breast, ovarian, pancreatic or prostate cancer.

Breast & Ovarian Cancer

Patients diagnosed with breast or ovarian cancer, especially at a younger age.

Suspected HBOC Syndrome

Individuals with clinical features suggesting Hereditary Breast & Ovarian Cancer Syndrome.

Clinical Recommendation

Patients advised by an oncologist or genetic counsellor to undergo hereditary cancer testing.

Sample Report

Clear, Comprehensive & Clinically Actionable Reports

The BRCA Germline report presents clinically relevant genetic findings in an easy-to-understand format, helping healthcare professionals make informed treatment and risk assessment decisions.

Detected Variants

Detailed description of identified BRCA1 & BRCA2 variants.

Clinical Interpretation

Variant classification based on current clinical guidelines.

Coverage & Quality Metrics

Sequencing quality indicators for confidence in results.

Actionable Recommendations

Clinical recommendations and guidance for follow-up care.

Why Neuberg

Why Choose Neuberg for BRCA Testing?

Combining advanced genomic technology with experienced molecular diagnostics, Neuberg delivers accurate, reliable, and clinically actionable genetic testing services.

Advanced NGS Platform

High-quality sequencing for comprehensive BRCA variant detection.

Expert Molecular Team

Reports reviewed by experienced molecular genetic specialists.

Actionable Reports

Comprehensive reports with clinically relevant interpretations.

Fast Turnaround

Delivering reliable BRCA reports in approximately 14 working days.

Take the Next Step

Take Control of Your Hereditary Cancer Risk with BRCA1 & BRCA2 Testing

Identify inherited BRCA1 & BRCA2 gene mutations with our advanced NGS-based germline test. Empower proactive healthcare decisions through accurate genetic insights, expert clinical interpretation, and comprehensive reporting.

Book This Test Download Brochure